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ABSTRACT
This study examined the contribution of AmpC over-expression to b-lactam resistance in clinical isolates
of Pseudomonas aeruginosa obtained from a hospital in Houston, TX, USA. Seventy-six non-repeat
bloodstream isolates obtained during 2003 were screened for ceftazidime resistance in the presence and
absence of clavulanic acid 4 mg ⁄L. AmpC was identiﬁed by isoelectric focusing (with and without
cloxacillin inhibition); stable derepression was ascertained phenotypically by a spectrophotometric
assay (with and without preceding induction by imipenem) using nitroceﬁn as the substrate, and was
conﬁrmed subsequently by quantitative RT-PCR of the ampC gene. The clonal relatedness of the AmpC-
over-expressing isolates was assessed by pulsed-ﬁeld gel electrophoresis. In addition, the ampC and
ampR gene sequences were determined by PCR and sequencing. For comparison, two standard wild-
type strains (PAO1 and ATCC 27853) and three multidrug-susceptible isolates were used as controls.
AmpC over-expression was conﬁrmed in 14 ceftazidime-resistant isolates (overall prevalence rate,
18.4%), belonging to seven distinct clones. The most prevalent point mutations in ampC were G27D,
V205L and G391A. Point mutations in ampR were also detected in eight ceftazidime-resistant isolates.
AmpC over-expression appears to be a signiﬁcant mechanism of b-lactam resistance in P. aeruginosa.
Understanding the prevalence and mechanisms of b-lactam resistance in P. aeruginosa may guide the
choice of empirical therapy for nosocomial infections in hospitals.
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INTRODUCTION
Pseudomonas aeruginosa is an important pathogen
associated with serious nosocomial infections such
as pneumonia and sepsis. In 2003, P. aeruginosa
was the most commonly isolated Gram-negative
species causing nosocomial pneumonia, and the
third most commonly isolated Gram-negative
species causing nosocomial urinary tract infection
in the USA [1]. Bloodstream infections caused by
P. aeruginosa have been associated with mortality
rates of 18–62% [2]. Furthermore, P. aeruginosa is
also associated with multiple mechanisms of
antibiotic resistance, including b-lactamase pro-
duction, porin channel deletion, efﬂux pump over-
expression, multi-functional group transferases,
and target site mutations. [3].
Treatment of pseudomonal infections often
represents a challenge for clinicians. Some of the
mechanisms of resistance are highly speciﬁc for
one speciﬁc antimicrobial agent, while others
affect a broad spectrum of agents and confer
different levels of resistance. There are very few
new antimicrobial agents in an advanced stage of
development that are designed to target Gram-
negative bacteria, and none are expected to be
available for clinical use in the next decade. Given
that the drug development process takes many
years, it is critical that the clinical efﬁcacy of
currently available agents is preserved and that
new agents are developed against these bacteria.
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AmpC is normally a chromosomally-mediated
b-lactamase that is expressed constitutively, with
expression regulated transcriptionally by ampR.
In contrast to a large number of plasmid-medi-
ated b-lactamases, the hydrolytic activity of
AmpC is not inhibited by b-lactamase inhibitors
(e.g., clavulanic acid) [4]. Point mutations in ampR
have been associated with stable derepression of
ampC, resulting in b-lactam resistance in Entero-
bacter cloacae [5], but it is not known whether this
is also true for P. aeruginosa.
The prevalence of ceftazidime resistance among
clinical isolates of P. aeruginosa in France has been
reported as 6%, primarily because of AmpC over-
expression [6]. The objective of the present study
was to determine the prevalence of AmpC over-
expression among bloodstream isolates of P. aeru-
ginosa in the USA. An improved understanding of
the prevalence and mechanisms of b-lactam resist-
ance in P. aeruginosa may help to guide formulary
decisions and the choice of empirical therapy for
nosocomial infections in hospitals.
MATERIALS AND METHODS
Bacteria and resistance screening
All non-repeat (>7 days apart) bloodstream isolates of
P. aeruginosa from 2003, together with their susceptibility
results, were obtained from the clinical microbiology laborat-
ory of St Luke’s Episcopal Hospital, a 664-bed university-
afﬁliated teaching hospital in Houston, TX, USA. The isolates
were screened for ceftazidime resistance (deﬁned as an MIC
>8 mg ⁄L) in the presence and absence of clavulanic acid
4 mg ⁄L, using Etests (AB Biodisk, Piscataway, NJ, USA),
according to the manufacturer’s instructions, to assess possible
resistance caused by AmpC over-expression.
Spectrophotometric assay
Increased b-lactamase activity was conﬁrmed by a spectro-
photometric assay using nitroceﬁn as the substrate (with and
without preceding induction by imipenem) [7]. In brief, 1 mL
of an overnight culture was diluted 20-fold with pre-warmed,
cation-adjusted Mueller–Hinton broth (Becton Dickinson,
Sparks, MD, USA) and incubated in a shaking water bath at
37C for 90 min. Imipenem was added to a concentration of
0.5 mg ⁄L (0.25 · the MIC for the wild-type isolate) for enzyme
induction. The cells were incubated for a further 2.5 h before
being harvested by centrifugation (5000 g at 37C for 15 min),
washed once with 100 mM phosphate buffer (pH 7.0), and
then resuspended in 1 mL of phosphate buffer. Lysis of the
outer-membrane of the cells was achieved by two cycles of
freezing ()20C) and thawing. Membranes and residual cells
were removed by centrifugation (20 000 g at 4C for 30 min).
The enzymic activity of the crude cell lysate was determined
spectrophotometrically at 486 nm using 100 lM nitroceﬁn
(Oxoid, Ogdensburg, NY, USA) in 100 mM phosphate buffer
and 1 mM EDTA (pH 7.0) at 30C. The protein content of the
crude cell lysate was determined with a bicinchoninic acid
protein assay reagent kit (Pierce Biotechnology, Rockford, IL,
USA), following the manufacturer’s instructions. The standard
wild-type strain ATCC 27853 and three clinical multidrug-
susceptible isolates were used as controls.
Analytical isoelectric focusing (IEF)
IEF was used to identify the b-lactamase(s) responsible for
accelerated hydrolysis of nitroceﬁn. Bacterial lysates were
prepared as described previously [8]. IEF standards were
purchased from Bio-Rad (Hercules, CA, USA). Identiﬁcation of
b-lactamase bands was facilitated by overlaying gels with
1 mM nitroceﬁn in 100 mM phosphate buffer (pH 7.0). An
analytical IEF inhibition assay was performed by overlaying
the gel with 0.3 mM cloxacillin in 100 mM phosphate buffer
(pH 7.0) before overlaying with nitroceﬁn [9].
Quantitative RT-PCR (RT-qPCR)
The relative level of ampC expression was determined by
RT-qPCR. Total RNA was isolated from bacterial cultures
(c. 2–4 · 108 cells in logarithmic growth phase) using an
RNeasy mini kit and RNAprotect bacteria reagent (Qiagen,
Valencia, CA, USA) according to the manufacturer’s instruc-
tions. Reverse transcription to cDNA was performed using a
GeneAmp RNA PCR kit (Applied Biosystems, Foster City, CA,
USA) with random hexamers. The DNA samples were
analysed in triplicate using an ABI PRISM 7000 (Applied
Biosystems) in conjunction with the primers and dual-labelled
ﬂuorescent hybridisation probes listed in Table 1. The thresh-
old cycle (Ct) of each sample, which identiﬁed the PCR cycle at
which the ﬂuorescence exceeded a threshold value, was
calculated by the ABI PRISM software. The rpoD housekeeping
gene was used as an internal standard [10]; rpoDwas ampliﬁed
in separate qPCR reactions to correct for percentage differ-
ences in RNA recovery. The relative expression of ampC was
assessed using the DDCt method as described previously [11].
The wild-type strain ATCC 27853 was used as a control.
Pulsed-ﬁeld gel electrophoresis (PFGE)
The clonal relatedness of the isolates that screened positive
for AmpC over-expression was assessed using PFGE.
Table 1. Oligonucleotides used for ampliﬁcation and ⁄or
sequencing
Primer ⁄probe Sequence Positiona
(A) RT-qPCR
AMPC-F 5¢-CGCCGTACAACCGGTGAT 673
AMPC-R 5¢-GAAGTAATGCGGTTCTCCTTTCA 754
AMPC-probe 5¢-AAGGCCAATGACATTCCGGGC 692
RPOD-F 5¢-CAGCAATCTCGTCTGAAAGAGTTG 19
RPOD-R 5¢-TTGATCCCCATGTCGTTGATC 167
RPOD-probe 5¢-ACCACCTGCCGGAGGATATTTCCGAT 92
(B) PCR
AMPC-F 5¢-GGGGCGGTTTCTCATGCAGCCAACG 510
AMPC-R 5¢-GAAGCGCTCATGGCACCATCATAGCC 1820
AMPR-F 5¢-AGGATTGGCGTCCTTTGTC 13
AMPR-R 5¢-CTTGAATCGCCTGCATAACC 1071
aNumbers correspond to the position of the ﬁrst 5¢ base of each oligonucleotide
according to the numbering of the nucleotide sequences in GenBank, accession
numbers X54719 (ampC), X67095 (ampR), and AE004494 (rpoD).
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Chromosomal DNA was prepared from each strain as des-
cribed previously [12], with the following modiﬁcations:
overnight bacterial cultures were grown in cation-adjusted
Mueller–Hinton broth; DNA was digested with XbaI (Invitro-
gen, Carlsbad, CA, USA) overnight at 35C; and the samples
were analysed using the CHEF MAPPER system (Bio-Rad
Laboratories, Richmond, CA, USA) at 6.0 V ⁄ cm for 21 h, with
linear pulse times ramped from 1 to 25 s.
Sequencing of ampC and ampR
The ampC and ampR genes of isolates that screened positive for
AmpC stable derepression were ampliﬁed by PCR. Genomic
DNA was extracted using a QIAamp DNA mini kit (Qiagen),
following the manufacturer’s instructions, and 50 ng of ge-
nomic DNA was used as a PCR template. Reaction mixtures
(ﬁnal volume 50 lL) contained 1 U of Taq DNA polymerase,
0.5 lM each primer (Table 1), 10 mM Tris-HCl, 50 mM KCl,
2.5 mM MgCl2 and 250 lM each dNTP. The PCR comprised
94C for 10 min, followed by 35 cycles of 94C for 1 min, 58C
(ampC) or 55C (ampR) for 1 min and 72C for 2 min, with a
ﬁnal extension at 72C for 10 min. Sequences of the PCR
products were subsequently determined using an ABI 3730 XL
DNA analyser (Applied Biosystems) and were compared with
the wild-type PAO1 sequences in GenBank, accession numbers
X54719 (ampC) and X67095 (ampR).
RESULTS
Bacteria and resistance screening
In total, 76 P. aeruginosa isolates (from 63 patients)
were available, of which 15 (19.7%) were resistant
to ceftazidime (MIC >8 mg ⁄L). All patients had
been hospitalised for ‡48 h, and no patient was
diagnosed with cystic ﬁbrosis. Susceptibilities of
the isolates to other antimicrobial agents are
shown in Fig. 1. Susceptibility to ceftazidime
was not enhanced in the presence of clavulanic
acid (ceftazidime MIC >4 mg ⁄L for all 15 iso-
lates), suggesting that an extended-spectrum
b-lactamase (e.g., SHV- or TEM-type) was not
the sole mechanism of ceftazidime resistance.
Spectrophotometric assay and IEF
The enzymic activities of thewild-type isolatewere
found to be 52.5 U ⁄mg (non-induced) and 8760 U ⁄
mg (induced) (1 U of enzyme hydrolyses 1 nmol
nitroceﬁn ⁄min at 30C with a nitroceﬁn concen-
tration of 100 lM). Induction by imipenem resul-
ted in a >150-fold increase in enzymic activity in
the wild-type isolate. The enzymic activity of the
multidrug-susceptible isolates (non-induced) was
comparable with that of the wild-type isolate (all
<four-fold different). In contrast, 14 of the 15
ceftazidime-resistant isolates (non-induced) had a
>20-fold increase in enzymic activity compared
with the wild-type (Table 2). Induction by imipe-
nem resulted in a <ten-fold further increase in
enzymic activity in these 14 resistant isolates (data
not shown), consistent with (partially) stable
derepression. The remaining ceftazidime-resistant
isolate (PA 1616) had enzymic activity similar to
that of the wild-type. This isolate was also
resistant to piperacillin–tazobactam, meropenem,
ciproﬂoxacin and levoﬂoxacin, suggesting that
over-expression of efﬂux pumps (e.g., MexAB–
OprM) might be responsible for ceftazidime
resistance, and was therefore not evaluated
further.
IEF analysis of extracts from the remaining 14
ceftazidime-resistant isolates revealed a b-lact-
amase of pI 8.7 that was inhibited by cloxacillin in
all 14 isolates, i.e., consistent with the chromo-
somal AmpC enzyme of P. aeruginosa [13].
Furthermore, only a single b-lactamase band
was observed in 13 isolates; isolate PA 1872
produced an additional b-lactamase of pI 5.7,
consistent with a b-lactamase belonging to the
TEM family.
RT-qPCR
The relative expression of the ampC gene in the
ceftazidime-resistant isolates is summarised in
Table 2. All three multidrug-susceptible isolates
showed similar expression of ampC. However,
none of the ceftazidime-resistant isolates had a
relative gene expression that was >ﬁve-fold that
of the wild-type control. The enhanced enzymic
activity observed could not be fully explained by
the difference in transcription levels.
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Fig. 1. Resistance proﬁles of Pseudomonas aeruginosa blood-
stream isolates (n = 76) to antimicrobial agents (AmpC+,
AmpC over-expressed; AmpC–, AmpC not over-ex-
pressed, i.e., similar to wild-type).
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PFGE typing
The patterns of the genomic DNAs digested with
XbaI endonuclease revealed seven distinct clones
(Table 2), as suggested by a difference of seven or
more DNA bands [14]. Two sub-clones (differing
by four bands) were identiﬁed for one of the
clones.
Sequencing of ampC and ampR
Multiple point mutations in ampC were identiﬁed.
Compared to PAO1, several point mutations
(R79Q, T105A, G186S and A397R) were detected
in the standard wild-type strain ATCC 27853
(susceptible to ceftazidime), suggesting that these
point mutations were unlikely to be involved in
ceftazidime resistance. A summary of the other
point mutations resulting in amino-acid changes
is provided in Table 2. Similarly, point muta-
tion(s) in ampR were also detected in eight
ceftazidime-resistant isolates. Point mutations
(A12R and G237A) were detected in the standard
wild-type strain ATCC 27853, suggesting that
these point mutations were also unlikely to be
involved in ceftazidime resistance. A summary of
the other point mutations resulting in amino-acid
changes is shown in Table 3.
DISCUSSION
P. aeruginosa is one of the most common patho-
gens implicated in serious nosocomial infections
such as pneumonia and sepsis. Treatment of
pseudomonal infections often represents a chal-
lenge to clinicians. Resistance to the b-lactams has
been reported and is becoming more prevalent
[15]. If the rapid spread of resistance is un-
checked, there is a serious threat of a return to the
pre-antibiotic ara, wiping out the great advances
achieved a generation ago in the control of
infectious diseases [16]. Clearly, understanding
the prevalence and mechanisms of b-lactam
resistance is important in optimising treatment
of infections caused by these resistant pathogens.
Resistance to the b-lactams in P. aeruginosa
may be mediated by several mechanisms, e.g.,
chromosomally-mediated b-lactamase (AmpC),
Table 2. Point mutations detected in ampC, relative expression (non-induced) and ceftazidime susceptibility of isolates
Isolate Clone
Point mutations resulting in amino-acid changes at position Relative expression (fold-difference)
Ceftazidime
MIC (mg ⁄L)21 27 97 205 391 Enzymic activity Transcription
PA 27853a – 1.0 (reference) 1.0 (reference) 1
PA 2828b – 3.9 0.9 1.5
PA 2599b – 2.6 0.9 1
PA 2905b – 1.9 0.8 1.5
PA 1843c 1 58.1 1.1 64
PA 1872c 2 386.4 1.0 48
PA 1962c 1 34.1 1.3 24
PA 1975c 1 38.6 2.1 48
PA 2026 3 T21A V205L G391A 2000.3 3.3 >256
PA 2040 3 T21A V205L G391A 1375.6 4.2 >256
PA 2041 3 T21A V205L G391A 2111.4 3.1 >256
PA 2205 4 G27D A97V V205L G391A 107.4 3.5 48
PA 2300 4 G27D A97V V205L G391A 22.0 1.0 32
PA 2431 5 G27D A97V V205L G391A 280.3 1.5 96
PA 2484 4a G27D A97V V205L G391A 272.0 2.0 96
PA 2493 4 G27D A97V V205L G391A 30.2 1.0 32
PA 2924 6 G27D V205L G391A 22.6 2.1 16
PA 2973 7 G27D A97V V205L G391A 389.5 1.1 32
aATCC standard wild-type strain.
bClinical multidrug-susceptible isolate.
cPoint mutation not detected compared with PA 27853.
Table 3. Point mutations detected in ampR among ceftaz-
idime-resistant isolates of Pseudomonas aeruginosa
Isolate
Point mutations resulting in amino-acid changes at position
114 282 283 288
PA 1843a
PA 1872a
PA 1962a
PA 1975a
PA 2026a
PA 2040 G283E M288R
PA 2041a
PA 2205 G283E M288R
PA 2300 G283E M288R
PA 2431 G283E M288R
PA 2484 R282T G283E M288R
PA 2493 G283E
PA 2924 E114A G283E M288R
PA 2973 G283E M288R
aPoint mutation not detected compared with the ATCC standard wild-type strain
PA 27853.
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plasmid-mediated b-lactamases (SHV and TEM),
integron-associated metallo-b-lactamases (VIM
and IMP), outer-membrane porin (OprD) dele-
tions, and the over-expression of efﬂux pumps
(MexAB–OprM). With a good understanding of
the mechanisms of b-lactam resistance prevalent
in a hospital, effective empirical therapy for
nosocomial infections can be formulated ration-
ally. For example, b-lactam ⁄b-lactamase inhibitor
combinations may not be appropriate as empirical
therapy in hospitals where AmpC over-expres-
sion is prevalent, as the hydrolytic activity of
AmpC is not inhibited effectively by clinically-
available b-lactamase inhibitors (as demonstrated
with clavulanic acid in the present study). A
carbapenem (e.g., meropenem or imipenem) or a
non-b-lactam agent may be preferred as empirical
therapy, since these agents are stable against
hydrolysis mediated by AmpC.
The present study investigated the prevalence
of AmpC over-expression as a mechanism of
resistance responsible for b-lactam resistance in
P. aeruginosa obtained from a hospital in Houston,
TX, USA. In bloodstream isolates, the overall
resistance rates ranged from <1% (amikacin) to
36% (levoﬂoxacin). Among the b-lactams, resis-
tance rates ranged from 13% (meropenem) to 25%
(cefepime). Extended-spectrum b-lactamases were
not prevalent among ceftazidime-resistant iso-
lates, and ceftazidime resistance was associated
primarily with AmpC over-expression, as identi-
ﬁed by IEF and ascertained phenotypically in this
study. While the increased b-lactamase activity
(over-expression of AmpC) observed phenotypi-
cally correlated somewhat with ceftazidime sus-
ceptibility (MIC), it could not be explained simply
by increased transcription of ampC. The increase in
substrate hydrolysis among the ceftazidime-resist-
ant isolates ranged from 22.6- to 2111.4-fold,
compared with up to a 4.2-fold increase in ampC
expression (transcription). The hydrolytic activity
of AmpC could have been enhanced by trans-
lational differences. Alternatively, it is also poss-
ible that point mutation(s) in ampC may have
increased the enzymic efﬁciency of AmpC. This
latter suggestion is supported by the observation
that the three isolates with the highest enzymic
activity and MIC (i.e., PA 2026, PA 2040 and
PA 2041) were clonally related and had identical
point mutations in ampC. In particular, the T21A
point mutation was not observed in any other
isolate investigated, and could therefore be the
focus of future studies. The results of the present
study provide sufﬁcient evidence to conclude that
ceftazidime resistance was associated predomin-
antly with enhanced activity of AmpC.
Point mutations in ampR have been shown to be
associated with stable derepression of ampC,
resulting in b-lactam resistance in E. cloacae [5]
and P. aeruginosa [17]. However, the underlying
molecular events leading to AmpC over-expres-
sion may be much more complex in P. aeruginosa.
The ampR gene in P. aeruginosa is thought to be a
global regulator for more than one gene; thus, it
regulates the expression of ampC, poxB, lasR, etc.,
but does not auto-regulate its own promoter [18].
The ampC–ampR genetic region in isolates ob-
tained from cystic ﬁbrosis patients has been
reported to be highly conserved [19]. However,
in the present study, point mutation(s) in ampR
were common in isolates derived from non-cystic
ﬁbrosis patients, despite their clonal diversity.
The role of speciﬁc point mutations in ampC or
ampR was not investigated using complementa-
tion studies, which would have been beyond the
focus of the present study. However, there were
four ceftazidime-resistant isolates without a point
mutation in either ampC or ampR; therefore,
ceftazidime resistance mediated by b-lactamase
over-production could not be attributed solely to
mutations in these genes. In this respect, it has
been reported previously that AmpC hyper-pro-
duction in clinical isolates of P. aeruginosa lacking
mutations in ampR or the ampC–ampR intergenic
region may be caused by AmpD ⁄ ampD inactiva-
tion [20,21]. An insertion sequence located in the
ampD gene has been associated with high-level
expression of AmpC [17], and transcription of
ampC has been reported to be regulated in a
stepwise manner by various AmpD homologues
[22]. Furthermore, AmpE may also play an indi-
rect role in ceftazidime resistance [20].
In conclusion, the molecular events leading to
over-expression of AmpC are clearly important in
understanding bacterial resistance. The present
study found that the prevalence of AmpC over-
expression was 18.4% among bloodstream iso-
lates of P. aeruginosa. In contrast to the ﬁndings
of a previous study [6], AmpC over-expression
appears to be a signiﬁcant mechanism of b-lactam
resistance in P. aeruginosa. Understanding the
prevalence and mechanisms of b-lactam resist-
ance in P. aeruginosa may guide the choice of
empirical therapy for nosocomial infections.
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